Evidence map›Paper›PMID 34608330›Full record

ArticleNature medicine2021

Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce.

Qian Li, Carolina E Hagberg, Helena Silva Cascales, Shuai Lang, Mervi T Hyvönen, Firoozeh Salehzadeh, Ping Chen, Ida Alexandersson, Eleni Terezaki, Matthew J Harms and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Youthfulness of marrow AdipoqBone research · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Inflammation and Resolution in Obesity-Related Cardiovascular Disease.International journal of molecular sciences · 2026
    Review
  18. Article
  19. Review
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Qian Li *Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-9895-1415
Carolina E Hagberg *Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-5497-2855
Helena Silva CascalesKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Shuai LangDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Mervi T HyvönenDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5517-7442
Firoozeh SalehzadehKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Ping ChenKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8068-1891
Ida AlexanderssonBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0003-3038-3893
Eleni TerezakiKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5836-0672
Matthew J HarmsBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Maria KutschkeKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Nahida ArifenKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Niels KrämerDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Myriam AouadiKarolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI/AZ ICMC), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6256-7107
Carole KnibbeCarMeN Laboratory, Lyon University, INRIA, INSA Lyon, Lyon, France.
Jeremie BoucherBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Anders ThorellDepartment of Clinical Science, Danderyds Hospital, Karolinska Institutet and Department of Surgery, Ersta Hospital, Karolinska Institutet, Stockholm, Sweden.
Kirsty L SpaldingDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden. kirsty.spalding@ki.se.ORCID http://orcid.org/0000-0002-5189-7028
Karolinska Institutet · SEAstraZeneca (Sweden) · SEInstitut national de recherche en sciences et technologies du numérique · FRStockholm University · SEUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is considered an important factor for many chronic diseases, including diabetes, cardiovascular disease and cancer. The expansion of adipose tissue in obesity is due to an increase in both adipocyte progenitor differentiation and mature adipocyte cell size. Adipocytes, however, are thought to be unable to divide or enter the cell cycle. We demonstrate that mature human adipocytes unexpectedly display a gene and protein signature indicative of an active cell cycle program. Adipocyte cell cycle progression associates with obesity and hyperinsulinemia, with a concomitant increase in cell size, nuclear size and nuclear DNA content. Chronic hyperinsulinemia in vitro or in humans, however, is associated with subsequent cell cycle exit, leading to a premature senescent transcriptomic and secretory profile in adipocytes. Premature senescence is rapidly becoming recognized as an important mediator of stress-induced tissue dysfunction. By demonstrating that adipocytes can activate a cell cycle program, we define a mechanism whereby mature human adipocytes senesce. We further show that by targeting the adipocyte cell cycle program using metformin, it is possible to influence adipocyte senescence and obesity-associated adipose tissue inflammation.

Indexed as

AdipocytesAdipose TissueCell CycleCell DifferentiationCellular SenescenceCyclin D1HumansHyperinsulinismHypoglycemic AgentsMetforminObesityCCND1 protein, humanCyclin D1Hypoglycemic AgentsMetformin

Identifiers

PMID34608330
OpenAlexW3202949712

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.